PHARMALINKFHI RENEWS LICENSE AGREEMENT WITH PHASE FORWARD
Company Relies on Phase Forward's InForm EDC Solution to Accelerate Clinical Data Collection and Analysis
Waltham, Mass. – March 23, 2006 – Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced PharmaLinkFHI (PharmaLink), a leading electronic clinical research organization (eCRO), has signed a three-year license agreement to extend its use of Phase Forward's InForm™ Web-based solution for electronic data capture (EDC). A longtime strategic partner, PharmaLink plans to continue to leverage Phase Forward's InForm as one of its primary EDC tools.
With the InForm solution, PharmaLink can help its clients quickly and efficiently access, analyze and report critical clinical data. Because InForm offers enterprise-level scalability - to thousands of sites and tens of thousands of patients - and extensive functionality in an intuitive user interface, clinical development staff can do more faster and with greater accuracy.
"As the leading eCRO conducting all of our trials in EDC, we realized InForm's benefits long ago and have shared many successful implementations with Phase Forward during our strong, six-year partnership," said Richard Staub, president and chief operating officer, PharmaLink. "Because of the increased efficiency it affords, we integrated InForm with our Web-based clinical trial management and reporting system (CTMS), InfoLink. By leveraging the data visibility afforded by our technology platform, combined with our high efficiency clinical processes, we've reduced the time from Last Patient/Last Visit to database lock to between three to eight working days. In addition to its functionality, Phase Forward's worldwide experience will be particularly critical to PharmaLink as we anticipate future global engagements."
"As a firm that's focused on real-time clinical trial management, PharmaLink is at the vanguard of technology adoption," said Bob Weiler, president and chief executive officer, Phase Forward. "The company has pioneered best practices to ensure quality and provide high levels of visibility into the clinical trial process. We are pleased to be working with such a committed partner."
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
